69455-12-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(benzyloxy)-3-bromobenzenecarbaldehyde serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique structure and functional groups facilitate the development of new drug molecules, contributing to advancements in medicinal chemistry.
Used in Fragrance and Flavoring Production:
4-(benzyloxy)-3-bromobenzenecarbaldehyde is also utilized in the production of fragrances and flavorings, capitalizing on its reactivity and aromatic properties to create a diverse range of scents and tastes for consumer products.
Used in Organic Chemistry Research:
Due to its potential applications and the presence of multiple reactive sites, 4-(benzyloxy)-3-bromobenzenecarbaldehyde is a valuable compound in the field of organic chemistry. It is employed in research to explore new reactions and synthetic pathways, thereby expanding the horizons of chemical knowledge and application.

InChI:InChI=1/C14H11BrO2/c15-13-8-12(9-16)6-7-14(13)17-10-11-4-2-1-3-5-11/h1-9H,10H2

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 100-44-7 benzyl chloride 
• 123-08-0 4-hydroxy-benzaldehyde 
• 100-39-0 benzyl bromide 

Downstream Products

• 115439-19-5 1-Benzyloxy-2-bromo-4-dimethoxymethyl-benzene 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 868598-97-4 2-(4-benzyloxy-3-bromophenyl)-1,3-dioxolane 
• 1198307-62-8 (Z)-5-(4-benzyloxy-3-bromobenzylidene)thiazolidine-2,4-dione 
• 1198307-58-2 4-benzyloxy-3-phenylbenzaldehyde 
• 1254569-83-9 2,4'-dibenzyloxy-3'-bromodiphenylmethanol 
• 344944-84-9 C₁₈H₁₃BrN₂O₄ 
• 1395312-62-5 (Z)-methyl 3-(4-(benzyloxy)-3-bromophenyl)-2-(tert-butyldimethylsilyloxy)acrylate 
• 1395313-28-6 (E)-methyl 3-(4-(benzyloxy)-3-bromophenyl)-2-(tert-butyldimethylsilyloxy)acrylate 
• 898538-21-1 [4-(benzyloxy)-3-bromophenyl](4-ethoxyphenyl)methanol 
• 459430-90-1 [4-(benzyloxy)-3-bromophenyl]methanol 
• 372102-30-2 N-(3-{(E)-3-[4-(benzyloxy)-3-bromophenyl]-2-propenoyl}-2-hydroxy-5-methylphenyl)acetamide 
• 252578-40-8 4-(benzyloxy)-3-bromophenol 

Relevant academic research and scientific papers

PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF

This disclosure relates to medicines, and more particularly to a platelet aggregation inhibitor, a pharmaceutical composition containing the same and a preparation and application thereof. The platelet aggregation inhibitor provided herein is a compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer or a pharmaceutically-acceptable solvate thereof. This application also provides an application of the compound of formula (I), or a pharmaceutically-acceptable salt, a tautomer, a pharmaceutically-acceptable solvate or a pharmaceutical composition thereof in the treatment of thrombus.

Facile and divergent optimization of chromazonarol enabled the identification of simplified drimane meroterpenoids as novel pharmaceutical leads

The diversity of drimane hydroquinones was significantly expanded by the facile construction of (+)-chromazonarol relevant natural products, isomers, and analogues for the discovery of new pharmaceutical leads. The structure-activity relationship of (+)-c

Design, synthesis and biological evaluation of 1-hydroxy-2-phenyl-4-pyridyl-1H-imidazole derivatives as xanthine oxidase inhibitors

In our previous study, we reported a series of 1-hydroxy-2-phenyl-1H-imidazole-5-carboxylic acid derivatives that presented excellent in vitro xanthine oxidase inhibitory potency. As a continuation study, a series of 1-hydroxy-2-phenyl-1H-imidazole derivatives containing a pyridine moiety (4a-g and 5a-g) at the 4-position was designed and synthesized. Evaluation of in vitro xanthine oxidase inhibition demonstrated that the 4a-g series was more potent than the 5a-g series. Compound 4f was the most promising derivative in the series with an IC50 value of 0.64 μM. A Lineweaver-Burk plot revealed that compound 4f acted as a mixed-type xanthine oxidase inhibitor. An iso-pentyloxy group at the 4′-position improved the inhibitory potency. More interestingly, structure-activity relationship analysis indicated that the pyridine para-N atom played a crucial role in the inhibition. Molecular modeling provided a reasonable explanation for the structure-activity relationships observed in this study. In addition, a three dimensional quantitative structure-activity relationships model which possessed reasonable statistics (q2 = 0.885 and r2 = 0.993) was conducted to further understand the structural basis of these compounds as xanthine oxidase inhibitors. These compounds, especially compound 4f, have good potential for further investigations.

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

PERIPHERALLY RESTRICTED FAAH INHIBITORS

Peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH) are provided. The compounds can suppress FAAH activity and increases anandamide levels outside the central nervous system (CNS). Despite their relative inability to access brain and spinal cord, the compounds attenuate behavioral responses indicative of persistent pain in rodent models of inflammation and peripheral nerve injury, and suppresses noxious stimulus-evoked neuronal activation in spinal cord regions implicated in nociceptive processing. CBi receptor blockade prevents these effects. Accordingly, the invention also provides methods, and pharmaceutical compositions for treating conditions in which the inhibition of peripheral FAAH would be of benefit. The compounds of the invention are according to the formula (I): in which R1 is a polar group. In some embodiments, R1 is selected from the group consisting of hydroxy and the physiologically hydro lysable esters thereof. R2 and R3 are independently selected from the group consisting of hydrogen and substituted or unsubstituted hydrocarbyl; each R4 is independently selected from the group consisting of halogen and substituted or unsubstituted hydrocarbyl and n is an integer from 0 to 4; each R5 is independently selected from the group consisting of halo and substituted or unsubstituted hydrocarbyl and m is an integer from 0 to 3; and R6 is substituted or unsubstituted cyclohexyl; and the pharmaceutically acceptable salts thereof.

Fluorescent analogs of the marine natural product psammaplin A: Synthesis and biological activity

The symmetrical disulfide psammaplin A from the marine sponge Pseudoceratina sp. was synthesized and structurally altered by replacement of one of the α-(hydroxyimino)acyl units by a fluorescent 4-coumarinacetyl moiety. Thus, the first fluorescent analogs of psammaplin A were obtained. Structural variation also covered the substitution pattern of the phenyl ring. Cytotoxicity of psammaplin A against the mouse fibroblast cell line L-929 (IC50 0.42 μg mL-1) was about two-fold higher than that of the fluorescent hybrid compounds, whereas the disulfide containing two 4-coumarinacetyl moieties was inactive. Fluorescence microscopy revealed uptake of the 4-coumarinacetyl-α-(hydroxyimino)acyl hybrids into the cytoplasm leading to fluorescence in close proximity of the nuclear envelope, most likely in the Golgi apparatus. We did not observe strong fluorescence inside the nucleus, where most of the target histone deacetylases are located. We conclude that reduction of the disulfide probably takes place outside the nucleus. The psammaplin-derived thiol exhibited potent activity against histone deacetylase in the low nanomolar range, but diminished cytotoxicity. Antimicrobial activity of the new derivatives was also determined.

Synthesis of benzyloxycyanophenylboronic esters

The synthesis of six new benzyloxycyanoboronic esters: 2-benzyloxy-6- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (4a), 4-benzyloxy-2- cyanophenyl-4,4,5, 5-tetramethyl-[1,3,2]dioxaborolane (4b), 4-benzyloxy-3- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (8a), 2-benzyloxy-5- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]-dioxaborolane (8b), 3-benzyloxy-4- cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12a), and 2-benzyloxy-5-cyanophenyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (12b) is reported. Copyright by Walter de Gruyter Berlin Boston.

The first total synthesis of the natural product angoluvarin

The total synthesis of angoluvarin, a member of the dihydrochalcone family of natural products, is reported. Starting with 2-bromophenol, the synthesis was accomplished in eight steps with an overall yield of 2%. This represents the first reported synthes

Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects

Benzylidene-2,4-thiazolidinedione derivatives with substitutions on the phenyl ring at the ortho or para positions of the thiazolidinedione (TZD) group were synthesized as PTP1B inhibitors with IC50 values in a low micromolar range. Compound 3e, the lowest, bore an IC50 of 5.0 μM. In vivo efficacy of 3e as an antiobesity and hypoglycemic agent was evaluated in a mouse model system. Significant improvement of glucose tolerance was observed. This compound also significantly suppressed weight gain and significantly improved blood parameters such as TG, total cholesterol and NEFA. Compound 3e was also found to activate peroxisome proliferator-activated receptors (PPARs) indicating multiple mechanisms of action.